Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
Belite Bio, a biopharmaceutical company focused on untreatable eye diseases, will host a conference call on August 11, 2022, at 4:30 PM ET to discuss financial results for the first half of 2022.
The results will be released on August 10, 2022. Investors can join the call through a webcast or phone registration. The company is developing treatments for conditions like dry AMD and Stargardt disease.
- Conference call scheduled for August 11 to discuss financial results.
- Focus on developing treatments for untreatable eye diseases.
- Potential for significant market impact with successful product development.
- None.
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022.
Belite Bio, Inc First Half 2022 Financial Result Conference Call Information:
| Date: | Thursday, August 11, 2022 |
| Time: | 4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
| Webcast Link: | https://edge.media-server.com/mmc/p/duiw3n7s |
| Phone Registration Link: | https://register.vevent.com/register/BI1ef44339069942b696cb9a1a54d14d41 |
Webcast Link Instructions
You can join a live webcast of the conference by visiting the “Webcast” link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A reply will be available approximately two hours after the event for 30 days.
Phone Registration Instructions
To participate in the live call, please register using the “Phone Registration” link above. Once registered, you will receive dial-in numbers and unique PIN numbers via email. At the time of the call, you will dial in using the numbers from the confirmation email, and upon entering the unique PIN, will be routed into the call.
About Belite Bio
Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us the Company on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Important Cautions Regarding Forward Looking Statements
This press release contains certain "forward-looking statements" within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about Belite’s beliefs and expectations. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in Belite’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Media and Investor Relations Contact:
Jennifer Wu /ir@belitebio.com
Tim McCarthy /tim@lifesciadvisors.com
FAQ
When is the Belite Bio conference call for financial results?
What will be discussed in the Belite Bio conference call?
When will Belite Bio release its financial results?
What diseases does Belite Bio target?
